Tamoxifen (Soltamox) vs Vepdegestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

No aligned efficacy figure on record for this race.

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTamoxifen (Soltamox)Vepdegestrant
PFS, median20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result
OS, median47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
—Trial running · NCT05909397
ORR30%bn 47NCT0266866610.9% vs 3.6%vs Fulvestrantn 221NCT05654623
Clinical benefit rate64%bn 47NCT0266866634.3% vs 28.7%vs Fulvestrantn 274NCT05654623

PFS, median

Tamoxifen (Soltamox)
20.2 vs 15.6vs Endocrine Therapyn 173NCT00601900
2 other results
Vepdegestrant
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result

OS, median

Tamoxifen (Soltamox)
47.2 vs 43.9vs Endocrine Therapyn 173NCT00601900
1 other result
Vepdegestrant
—Trial running · NCT05909397

ORR

Tamoxifen (Soltamox)
30%bn 47NCT02668666
Vepdegestrant
10.9% vs 3.6%vs Fulvestrantn 221NCT05654623

Clinical benefit rate

Tamoxifen (Soltamox)
64%bn 47NCT02668666
Vepdegestrant
34.3% vs 28.7%vs Fulvestrantn 274NCT05654623
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Tamoxifen (Soltamox): 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTamoxifen (Soltamox)Vepdegestrant
Dropout rate
0%a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
0.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT01027416 · Phase na · registry result, not featured evidence
7.8%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
—
NCT00036270 · Phase 3 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
—
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—
NCT01027416 · Phase na · registry result, not featured evidence
—a
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
28.7%a
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
17.1%
NCT00036270 · Phase 3 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01027416 · Phase na · registry result, not featured evidence
4%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
hot flush 31.3%
arthralgia 23.8%
fatigue 16.4%
NCT00036270 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
arthralgia 33.3%
back pain 33.3%
headache 33.3%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
headache 32.1% (placebo 0%)
night sweats 32.1% (placebo 0%)
irritability 28.6% (placebo 0%)
NCT01027416 · Phase na · registry result, not featured evidence
a
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tamoxifen (Soltamox)

PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Disease Free Survival 352 vs 388 Tamoxifen Followed by Exemestane count @ 143wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
show 1 more result
712 vs 714 Tamoxifen Followed by Exemestane count @ 260wk
NCT00036270 · Phase 3 · registry result, not featured evidence
Overall Survival 485 vs 476 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
Relapse Free Survival 499 vs 521 Tamoxifen Followed by Exemestane count @ 260wk
event count · count
NCT00036270 · Phase 3 · registry result, not featured evidence
PFS 9.13 months
time to event · months
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
show 2 more results
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
ORR 30% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Clinical Benefit 64% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
OS Rate at 12 75.63% (n=49) @ 104wk
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Pathologic Complete 0% (n=23) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT02988986 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 1 more result
7.7% (n=13)*
NCT02806544 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
ORR 5.9% (n=17) @ 4wk
event count · % of participants
No placebo or comparator arm
NCT00118157 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 participants as posted
show 1 more result
18.6% (n=43) @ 24wk*
NCT00365599 · Phase 2 · registry result, not featured evidence · combination · converted to % from 8 participants as posted

+ 6 further endpoints in the CSV export.

Vepdegestrant

ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Tamoxifen (Soltamox)

Marketed by Mayne Pharma and partners

Approved in Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04174352 (registry estimate)

Reported efficacy

Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) (mixed)

Result source: NCT00066690

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Tamoxifen (Soltamox): 5 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTamoxifen (Soltamox)Vepdegestrant
PFS
time to event · months
20.2 vs 15.6 Endocrine Therapy monthsa,b,c
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
3.7 vs 3.6 Fulvestrant monthsd,a,b,c
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
5 vs 2.1 Fulvestrant months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Dropout rate
29.6%E+OFSe
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
26.7%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
10%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
9.1%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
99.2%
NCT01124695 · Phase 2 · registry result, not featured evidence
3.2%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
20%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
10.7%TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
0%
NCT01614210 · Phase 2 · registry result, not featured evidence
63.2%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
11.4%
NCT02806544 · Phase 2 · registry result, not featured evidence
0%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
17.6%
NCT00499083 · Phase 2 · registry result, not featured evidence
7.8%e
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
13.2%E+OFSe
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
6.8%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
—
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
—TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
—TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
—
NCT02668666 · Phase 2 · registry result, not featured evidence
8.9%
NCT01124695 · Phase 2 · registry result, not featured evidence
—Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
—Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
—high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
—
NCT01614210 · Phase 2 · registry result, not featured evidence
10.5%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
—
NCT02806544 · Phase 2 · registry result, not featured evidence
—
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
—
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
—
NCT00499083 · Phase 2 · registry result, not featured evidence
—e
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
37.5%E+OFSe
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
37.2%T+OFS
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
28.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
20.7%TC (Tamoxifen Control)
NCT00295646 · Phase 3 · registry result, not featured evidence
22.9%TZ (Tamoxifen+Zoledronate)
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
24.6%
NCT01124695 · Phase 2 · registry result, not featured evidence
0%Exemestane
NCT01831076 · Phase 2 · registry result, not featured evidence
0%Exemestane Plus Tamoxifen
NCT01831076 · Phase 2 · registry result, not featured evidence · combination
—TAK-228 Plus Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
3.6%TAK-228 and Tamoxifen
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
0%high dose
NCT03045653 · Phase 2 · registry result, not featured evidence
1.9%
NCT01614210 · Phase 2 · registry result, not featured evidence
100%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02806544 · Phase 2 · registry result, not featured evidence
9.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence
4%e
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
hot flashes/flushes 81.9%
pain - joint 77.7%
fatigue (asthenia, lethargy, malaise) 59%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 13 more results
hot flashes/flushes 80%
pain - joint 69.5%
sweating (diaphoresis) 61.7%
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
arthralgia 70.3%
hypertension 59%
proteinuria 47.7%
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
other/minor (not categorized) 24%
bone pain 20.9%
fatigue 15.6%
NCT00295646 · Phase 3 · registry result, not featured evidence
bone pain 29.3%
other/minor (not categorized) 24.9%
fatigue 18.2%
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
fatigue 14.8%
back pain 13.9%
nausea 11.5%
NCT01124695 · Phase 2 · registry result, not featured evidence
nausea 100%
NCT02988986 · Phase 2 · registry result, not featured evidence · combination
high dose
fatigue 23.3%
NCT03045653 · Phase 2 · registry result, not featured evidence
hot flashes 36.5%
nausea 21.2%
fatigue 9.6%
NCT01614210 · Phase 2 · registry result, not featured evidence
anemia 36.8%
nausea 36.8%
anorexia 31.6%
NCT00118157 · Phase 2 · registry result, not featured evidence · combination
fatigue - grade 2 18.6%
nausea - grade 2 18.6%
anorexia/weight loss - grade 2 16.3%
NCT00365599 · Phase 2 · registry result, not featured evidence · combination
hot flashes 58.3%
pain 41.7%
pain: breast 41.7%
NCT00952731 · Phase 2 · registry result, not featured evidence · combination
bone pain 33.3%
hypokalemia 33.3%
mucositis oral 33.3%
NCT00499083 · Phase 2 · registry result, not featured evidence
e
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: eligible sex differs (FEMALE versus ALL).
  2. bTreatment context differs: combination versus monotherapy.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tamoxifen (Soltamox)

Disease-free Survival 86.6% (n=1015) vs 84.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
89% (n=1014) vs 84.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Breast Cancer-free Interval 88.4% (n=1015) vs 86.4% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
90.9% (n=1014) vs 86.4% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Distant Recurrence-free Interval 91.3% (n=1015) vs 90.7% (n=1018) Tamoxifen @ 260wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
93% (n=1014) vs 90.7% (n=1018) Tamoxifen @ 260wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 93.3% (n=1015) vs 91.5% (n=1018) Tamoxifen @ 416wk
responder rate · % of participants
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
92.1% (n=1014) vs 91.5% (n=1018) Tamoxifen @ 416wk
NCT00066690 · Phase 3 · registry result, not featured evidence · combination
PFS-12 73% (n=173) vs 61% (n=170) Endocrine Therapy @ 52wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 87% (n=173) vs 77% (n=170) Endocrine Therapy @ 26wk
responder rate · % of participants
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 47.2 vs 43.9 Endocrine Therapy months
time to event · months
NCT00601900 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Disease-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
Recurrence-free Survival NA vs NA Anastrozole months
time to event · months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Anastrozole months
NCT00295646 · Phase 3 · registry result, not featured evidence
PFS 9.13 months
time to event · months
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
show 1 more result
5 months @ 156wkhigh dose
NCT03045653 · Phase 2 · registry result, not featured evidence
ORR 30% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence
Clinical Benefit 64% (n=47)
responder rate · % of participants
No placebo or comparator arm
NCT02668666 · Phase 2 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

Vepdegestrant

ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tamoxifen (Soltamox)'s landscape · Vepdegestrant's landscape